Dr. Howard Smith Oncall

  Vidcast:  https://youtu.be/u_XW1QD_308   Novavax, a nanoparticle complexed with a CoVid spike protein, is overall 89.7% effective.  This is similar to the Modern and Pfizer vaccines and about 20% better than the adenovirus vector J&J and Astrazeneca vaccines.  These results of a phase 3 study now appear in advance of its presentation to the FDA.   A total of 15,187 participants took part with half receiving the 2 shot vaccine.  Novavax is 96.4% effective against the original strain and 86.3% effective against the British B.1.117 variant.  The vaccine works for all ages and medical conditions.  Side effects are mild and more prominent after the second dose.   It may trigger longer-lasting immunity.  Stay tuned.   https://www.medrxiv.org/content/10.1101/2021.05.13.21256639v1.full.pdf+html   #novavax #nanoparticle #vaccine #CoVid